Global Conference 2023
Global Conference 2023

How Do Drugs Get Approved Faster Using RWE and AI?

-

Real-world evidence (RWE) and artificial intelligence (AI) have the potential to accelerate drug development via multiple mechanisms, providing valuable insights into drug safety and efficacy in the real-world setting. For instance, RWE may better identify patients most likely to benefit from a drug, enabling more efficient and targeted recruitment for clinical trials. Also, RWE is useful in monitoring drug safety and efficacy after approval, enabling earlier detection of adverse events and insight into broader indications. RWE can help identify patient subgroups most likely to respond to a particular treatment in diseases such as cancer, where targeted therapies are becoming the norm. Finally, RWE addresses gaps in knowledge of drug activity in populations historically under-represented in randomized clinical trials. However, important concerns remain to be addressed, including patient privacy, data quality, and regulatory acceptance of RWE. 

    Moderator

    Image

    William K. Oh

    Chief Medical Officer, Prostate Cancer Foundation

    Speakers

    Image

    Paul Boutros

    Director, Cancer Data Science, Jonsson Comprehensive Cancer Center; Professor of Human Genetics and Urology, UCLA David Geffen School of Medicine
    Image

    Mei Sheng Duh

    Managing Principal and Chief Epidemiologist, Analysis Group, Inc.
    Image

    Jack Hidary

    CEO, Sandbox AQ
    Image

    Susan Winckler

    CEO, Reagan-Udall Foundation for the Food and Drug Administration